This follows a similar move in September, when the co-operative announced it would upgrade plants in Lorneville and Pukeuri to process blood.
The facility will collect and process adult bovine blood into serum for blood products, which are used in the development of vaccines, cancer treatments, and drugs to treat neurodegenerative, haematological and endocrine disorders.
Chief executive David Surveyor said blood products can create value for the co-operative’s shareholders.
“Our strategy is maximising revenue, diversifying our products and strengthening our market channels.
“This investment is another example of how we are developing opportunities to capture more market value for our shareholders.”
